Physician profile
Shengxi Lin
NPI 1114192291
$1,958.97
in general payments reported to CMS, 2019-2025
15 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $141 · 2021: $149 · 2023: $16.68 · 2024: $869 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $376.57 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $263.44 | 2024-2025 | Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $188.50 | 2019-2024 | Invega Sustenna, Spravato |
| Alkermes, INC. | $180.29 | 2019-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $149.93 | 2021-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $148.12 | 2019 | |
| Neurocrine Biosciences, INC. | $139.52 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $116.37 | 2019-2024 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $103.53 | 2019-2020 | |
| Allergan, INC. | $57.00 | 2019 | |
| Indivior INC. | $51.53 | 2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $33.55 | 2019 | |
| Lundbeck LLC | $14.42 | 2019 | |
| Validus Pharmaceuticals LLC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shengxi Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.